SCHEMBL6551674

SCHEMBL6551674

CC(C)c1ccc([C@H](C)C(=O)O)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 10/20 0.65
PTGS1 P23219 8/20 0.61
AKR1C3 P42330 7/20 0.61
CYP2C9 P11712 6/20 0.61
AKR1C2 P52895 6/20 0.61
LMNA P02545 3/20 0.61
CXCR1 P25024 2/20 0.61
CXCR2 P25025 2/20 0.61
SLC22A6 Q4U2R8 2/20 0.61
TSHR P16473 2/20 0.61
ALB P02768 1/20 0.61
ESR1 P03372 1/20 0.61
ALOX5 P09917 1/20 0.61
RARB P10826 1/20 0.61
ADRB3 P13945 1/20 0.61
NFKB1 P19838 1/20 0.61
HTR2A P28223 1/20 0.61
NR1I3 Q14994 1/20 0.61
CXCL8 P10145 1/20 0.61
BLM P54132 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4651605 1.00 PTGS2 (0.65) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
SCHEMBL59197 0.92 PTGS2 (0.74) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
SCHEMBL480331 0.86 PTGS2 (0.61) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
SCHEMBL598280 0.86 PTGS2 (0.61) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
SCHEMBL2852282 0.86 PTGS2 (0.61) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
SCHEMBL121108 0.86 PTGS2 (0.61) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
SCHEMBL1590331 0.86 PTGS2 (0.61) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
SCHEMBL2818028 0.86 PTGS2 (0.61) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
SCHEMBL917093 0.85 PTGS2 (0.87) PTGS2PTGS1AKR1C3CYP2C9AKR1C2
Hydrochloric Acid SCHEMBL5846545 0.84 PTGS2 (0.59) PTGS2PTGS1AKR1C3CYP2C9AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7893094-B2 Amphiphilic pyridinium compounds, method of making and use thereof THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) 2011-02-22 US disclosed
US-7893094-B2 Amphiphilic pyridinium compounds, method of making and use thereof THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. (US) 2011-02-22 US disclosed
US-20070105916-A1 Amphiphilic pyridinium compounds, method of making and use thereof THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. 2007-05-10 US disclosed
US-20070105916-A1 Amphiphilic pyridinium compounds, method of making and use thereof THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. 2007-05-10 US disclosed
EP-1385824-A2 COMPOUNDS CO-INDUCING CHOLINERGIC UP-REGULATION AND INFLAMMATION DOWN-REGULATION AND USES THEREOF ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) 2004-02-04 EP disclosed
US-20020160988-A1 Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH 2002-10-31 US disclosed
WO-2002065977-A2 COMPOUNDS CO-INDUCING CHOLINERGIC UP-REGULATION AND INFLAMMATION DOWN-REGULATION AND USES THEREOF ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) 2002-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105916-A1 Amphiphilic pyridinium compounds, method of making and use thereof CXCL8, IL18, CCR8 PTGS2 544/4885PTGS1 421/4885AKR1C3 586/4885
US-20020160988-A1 Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof CHAT, ACHE, CHRNB2 PTGS2 65/4885PTGS1 63/4885AKR1C3 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.